<DOC>
	<DOCNO>NCT02926742</DOCNO>
	<brief_summary>This single site study evaluate efficacy ultrasound accelerate thrombolysis use EKOS Endovascular Device standard infusion thrombolytic treatment PE</brief_summary>
	<brief_title>Submassive Pulmonary Embolism Experience With EKOS</brief_title>
	<detailed_description>Previous clinical trial examine thrombolytic use treat Acute Submassive PE , many time use fix dose duration . Little research conduct physiologic implication resolution symptom . It seem reasonable , symptomatic relief result degree hemodynamic normalization . This study seek examine extent hemodynamic impairment normalize thrombolytic treatment protocol endpoint therapy determine resolution presenting symptom . Treatment plan utilize MBS ( Modified Borg Scale ) score help evaluate measure outcome-based care , quantify shortness breath .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<criteria>1 . Acute symptomatic PE confirm CT , fill defect least one main segmental pulmonary artery . 2 . RV dysfunction evidence RV/LV ratio &gt; 0.9 echo 3 . Ability give inform consent Legally Authorized Representative ( LAR ) able give consent 4 . PE symptom duration &lt; 21 day 5 . Age &gt; 18 year 6 . And , MBS baseline measurement 3 plus least one following : O2 sit &lt; 90 % RA , inability maintain HR &lt; 100 , inability maintain Systolic Bp &gt; 100 . Whichever measurement choose inclusion criterion addition MBS also use determination therapeutic endpoint ( i.e . O2 Sat. , HR &lt; 100 BP &gt; 100 ) .. 1 . Stroke transient ischemic attack ( TIA ) , head trauma , active intracranial intraspinal disease within one year 2 . Recent ( within one month ) active bleed major organ 3 . Hemoglobin ( Hgb ) &lt; 8.0 4 . Platelets &lt; 60 thousand/ÂµL 5 . Major surgery within seven day 6 . Clinician deems highrisk catastrophic bleed 7 . History heparininduced thrombocytopenia ( HIT ) 8 . Pregnancy 9 . Catheterbased pharmacomechanical treatment pulmonary embolism within 3 day study enrollment 10 . Systolic blood pressure le 80 mm Hg despite vasopressor inotropic support 11 . Cardiac arrest ( include pulseless electrical activity asystole ) require active cardiopulmonary resuscitation ( CPR ) 12 . Evidence irreversible neurological compromise 13 . Life expectancy &lt; 30 day 14 . Use thrombolytic glycoprotein IIb/IIIa antagonist within 3 day prior inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Thrombolysis</keyword>
	<keyword>Ultrasound Thrombolysis</keyword>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Saddle PE</keyword>
	<keyword>Submassive PE</keyword>
	<keyword>Massive PE</keyword>
	<keyword>Bilateral PE</keyword>
</DOC>